Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder

Nov 10 2009

• By The Pink Sheet Daily

Related Content

Roche’s Actemra Delayed By REMS, FDA Study Requirements

Dec 05 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window